- Price:
- $2.66
- Open:
- $2.50
- Previous close:
- $2.19
- Day's range:
- $2.26 - $2.78
- Year's range:
- $1.02 - $7.80
- Net Income per Share:
- -4.03
- Price-to-Earnings ratio:
- -0.66
- 52-week Price Range:
- $1.95
- Volume:
- $1,380,247.00
- Average volume:
- $72,206.00
Company profile for iBio, Inc.
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
- Stock exchanges:
- AMEX
- Sector:
- Healthcare
- Industries:
- Biotechnology
- Ticker:
- IBIO
- CIK:
- 0001420720
- ISIN:
- US4510332038
- Website:
- https://www.ibioinc.com
- Phone:
- 979 446 0027
- Origin:
- United States
- Employees:
- 105